Division of Genomic Medicine
Archive of Division of Genomic Medicine Programs
- The Genetic Association Information Network (GAIN)
Supported a series of Genome-Wide Association Studies (GWAS) designed to identify specific points of DNA variation associated with the occurrence of a particular common disease.
- Genomics and Randomized Trials Network (GARNET)
The Genomics and Randomized Trials Network (GARNET) is series of genome-wide association studies of treatment response in randomized clinical trials. The goal of GARNET was to identify genetic variants associated with response to treatments for conditions of clinical or public health significance.
- The Genes, Environment and Health Initiative (GEI)
Supported research to understand the genetic contributions and gene-environment interactions in common disease.
- GENEVA - Part of the Genetics Program of GEI, GENEVA (Gene Environment Association Studies) is using rapidly evolving technologies in Genome-Wide Association Studies (GWAS) to find genetic risk factors in common conditions, such as tooth decay, heart disease, cancer and diabetes, and assess their interplay with non-genetic risk factors.
- Making Every Voice Count: Public Consultation on Genetics, Environment, and Health
The goal of Making Every Voice Count, a project conducted by the Genetics & Public Policy Center of Johns Hopkins University [dnapolicy.org], was to obtain wide societal input to inform the design and implementation of a possible large U.S.-based longitudinal cohort study of the role of genes and environment in health and disease. This research project, initially funded for two years, resulted in the collection of rich and detailed data on the public's level of willingness to participate in such research, and the factors that influence these attitudes. A follow-up project is now underway to gather additional data on some of these issues. This study was conducted with partial support from the Ethical, Legal and Social Implications (ELSI) Research Program.
- Molecular Libraries and Imaging Program (MLI)
Created in 2005 under the NIH Common Fund to support the high-throughput screening of small molecules that could potentially be used by researchers for drug development or the study of cellular processes related to disease.
Top of page
Last Updated: August 11, 2015